Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical trials indicated to block biological pathways targeted by marketed injectable antibody drugs; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company also develops IL-17 oral peptide antagonist PN-88,1 an oral metabolic/obesity peptide program, and an oral hepcidin mimetic/ferroportin blocker that is in pre-clinical stage. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Protagonist Therapeutics Inc.

Citi analyst Geoff Meacham maintained a Buy rating on Protagonist Therapeutics on May 7 and set a price target of $130.00. The company’s shares clo...

Protagonist Therapeutics (PTGX) Receives a Buy from Citi

H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Protagonist Therapeutics today and set a price target of $117.00. Tsao covers the H...

H.C. Wainwright Sticks to Their Buy Rating for Protagonist Therapeutics (PTGX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on TScan Therapeutics (TCRX), Protagonist Therapeutics ...

Analysts Offer Insights on Healthcare Companies: TScan Therapeutics (TCRX), Protagonist Therapeutics (PTGX) and Disc Medicine (IRON)

In a report released today, Etzer Darout from Barclays maintained a Buy rating on Protagonist Therapeutics, with a price target of $119.00. Accordi...

Market Cap	$6.33B	P/E Ratio	30.39
52W High	$107.84	52W Low	$45.28
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	7.6%	52W Position	87.4%
Overall Score	56	Value Score	50
Quality Score	60	Technical Score	60

EPS Current Est	$3.29	EPS Next Est	$-1.35
EPS Growth Est	-141.0%	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	PTGX	$99.98	+0.80%	360.75K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	PTGX	$99.98	+0.8%	360.75K
3
4
5
6

PTGX

PTGX

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Protagonist Therapeutics Inc. Data in Excel

Get Protagonist Therapeutics Inc. Data in Excel